Compare SACH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | NXTC |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | 29 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.6M | 44.6M |
| IPO Year | N/A | 2019 |
| Metric | SACH | NXTC |
|---|---|---|
| Price | $0.96 | $11.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 161.8K | 25.8K |
| Earning Date | 03-12-2026 | 03-05-2026 |
| Dividend Yield | ★ 20.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,378,000.00 |
| Revenue This Year | $150.14 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.23 |
| 52 Week High | $1.35 | $15.74 |
| Indicator | SACH | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 45.47 |
| Support Level | N/A | $10.73 |
| Resistance Level | $1.12 | $13.47 |
| Average True Range (ATR) | 0.04 | 1.12 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 22.31 | 38.89 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.